The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
 
Zeynep Eroglu
Consulting or Advisory Role - Eisai; Elsevier; Genentech/Roche; OncoSec; Pfizer; Regeneron
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
James Moon
No Relationships to Disclose
 
Yana G. Najjar
Honoraria - Immunocore; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; InterVenn Biosciences; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - ISTARI Oncology
 
Rupesh Kotecha
Honoraria - Accuray; BrainLAB; Castle Biosciences; Elekta; Elsevier; Kazia Therapeutics; Peerview
Consulting or Advisory Role - Novocure; ViewRay
Speakers' Bureau - GT Medical Technologies (I); Novocure
Research Funding - AstraZeneca (Inst); Blue Earth Diagnostics (Inst); BrainLAB (Inst); Cantex Pharmaceuticals, Inc. (Inst); Exelixis (Inst); GT Medical Technologies (Inst); Medtronic (Inst); Novocure (Inst); ViewRay (Inst)
Travel, Accommodations, Expenses - Elekta; Novocure; Peerview; ViewRay
 
Vadim Spektor
No Relationships to Disclose
 
Michael Wu
No Relationships to Disclose
 
Elad Sharon
No Relationships to Disclose
 
Kenneth F. Grossmann
Employment - Merck
Consulting or Advisory Role - Array BioPharma; Bristo-Meyers Squibb; Natera; Novartis
 
Jedd D. Wolchok
Leadership - Ludwig Institute for Cancer Research
Stock and Other Ownership Interests - Apricity Therapeutics; Arsenal IO; Ascentage Pharma; CellCarta; Georgiamune; Imvaq Therapeutics; Larkspur; Linnaeus Therapeutics; Maverick Therapeutics; Tizona Therapeutics, Inc.; XenImmune Therapeutics
Consulting or Advisory Role - Amgen; Apricity Therapeutics; Ascentage Pharma; AstraZeneca; Bicara Therapeutics; Bristol-Myers Squibb; CellCarta; Daiichi Sankyo,Inc; Dragonfly Therapeutics; Georgiamune; Idera; Imvaq Therapeutics; Larkspur; Maverick Therapeutics; PsiOxus Therapeutics; Recepta Biopharma; Sellas Life Sciences; Surface Oncology; Tizona Therapeutics, Inc.; Trishula Therapeutics; Truvax; Werewolf Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Sephora
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2 (Inst); Anti-GITR antibodies and methods of use thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof CTLA 4 (Inst); CD40 BINDING MOLECULES AND USES THEREOF (Inst); CD40 binding Molecules and uses thereof (Inst); Engineered Vaccinia Viruses for Cancer Immunotherapy (Inst); I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells. (Inst); I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy (Inst); I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer (Inst); I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus. (Inst); I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals. (Inst); I am co-inventor and receive royalties for a patent for immune modulating antibodies. (Inst); Immunosuppressive follicular helper-like T cells modulated by immune checkpoint blockade (Inst); Peripheral Blood Phenotype Linked to Outcomes After Immunotherapy Treatment (Inst); Phosphatidylserine Targeting Agents and uses thereof for adoptive T-cell therapies (Inst); RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY (Inst); WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF MONITORING ABSCOPAL EFFECTS DURING SUCH TREATMENT (Inst)
 
Sapna Pradyuman Patel
Honoraria - Delcath Systems; Emory University
Consulting or Advisory Role - Bristol Myers Squibb; Castle Biosciences; Delcath Systems; immatics; Immunocore; Novartis; Pfizer; Replimune; TriSalus Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - InxMed; TriSalus Life Sciences
 
Hussein A. Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Medicenna; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst)